Bahar Arslan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bahar Arslan has a total of 197 co-authors. Here are the top co-authors by number of shared publications:
- Insu Yilmaz
Division of Immunology and Allergy, Department of Chest Diseases, Erciyes University Faculty of Medicine, Kayseri, Türkiye
17 shared publications - Gülden Paçacı Çetin
Department of Chest Diseases, Division of Allergy and Immunology, Erciyes University, School of Medicine
13 shared publications - Murat Türk
Division of Allergy and Clinical Immunology, Erciyes University School of Medicine, Kayseri, Turkey
10 shared publications - Murat Kavas
Department of Chest Diseases, University of Health Sciences, Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital
5 shared publications - Müge Erbay
Section of Immunology and Allergy Diseases, Department of Chest Diseases, Medical Faculty, Karadeniz Technical University, 61080 Trabzon, Turkey
5 shared publications - Ozcan Gul
Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey
5 shared publications
Latest Publications
- Open Access
- 13 January 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 32 (2) , 202-210
Anaphylaxis Awareness and Adrenaline Use Among Healthcare Professionals
Objective: Anaphylaxis is life-threatening and guidelines recommend adrenaline as a first-line treatment. However, previous studies have shown significant shortcomings in the appropriate management of anaphylaxis. Our study aimed to measure healthcare professionals’ current knowledge and experience with anaphylaxis and to raise awareness of anaphylaxis management and adrenaline use practices. Methods: The study included healthcare professionals working at Kayseri City Training and Research Hospital. A 19-question multiple-choice written questionnaire was performed face-to-face by an allergist. Inclusion criteria for the study were healthcare professionals (physician, nurse, paramedic) working in an inpatient or emergency department. Results: In the study of 260 participants, only 15% preferred “Inject adrenaline 0.5 mg (adult) or 0.3 mg (child) intramuscularly” as the correct first line step in the treatment algorithm and only 5% knew the correct sequence, and 88% had never used an adrenaline auto-injector. When comparing professions, physicians were found to have more accurate answers than nurses and paramedics for questions about diagnostic criteria, symptom recognition (p=0.007), the correct dose of adrenaline (p=0.001), and the correct route of administration (p=0.001). Both physicians and nurses preferred adrenaline as the first treatment drug (79.67%, n=192), followed by pheniramine (14.94%, n=36) and glucocorticoids (4.56%, n=11). Furthermore, 69.8% (n=167) of participants correctly answered the question about the adult adrenaline dose. Conclusion: Healthcare personnel, including physicians, lack sufficient knowledge of anaphylaxis diagnosis and treatment. Since anaphylaxis is a condition requiring urgent intervention and can be fatal if left untreated, the knowledge and skills of all personnel should be improved to minimize the risk of delayed treatment and serious complications.
- 13 January 2026
- Published by Pera Yayıncılık Hizmetleri in European Journal of Therapeutics
- Vol. 32 (2) , 202-210
Open AccessAnaphylaxis Awareness and Adrenaline Use Among Healthcare Professionals
Objective: Anaphylaxis is life-threatening and guidelines recommend adrenaline as a first-line treatment. However, previous studies have shown significant shortcomings in the appropriate management of anaphylaxis. Our study aimed to measure healthcare professionals’ current knowledge and experience with anaphylaxis and to raise awareness of anaphylaxis management and adrenaline use practices. Methods: The study included healthcare professionals working at Kayseri City Training and Research Hospital. A 19-question multiple-choice written questionnaire was performed face-to-face by an allergist. Inclusion criteria for the study were healthcare professionals (physician, nurse, paramedic) working in an inpatient or emergency department. Results: In the study of 260 participants, only 15% preferred “Inject adrenaline 0.5 mg (adult) or 0.3 mg (child) intramuscularly” as the correct first line step in the treatment algorithm and only 5% knew the correct sequence, and 88% had never used an adrenaline auto-injector. When comparing professions, physicians were found to have more accurate answers than nurses and paramedics for questions about diagnostic criteria, symptom recognition (p=0.007), the correct dose of adrenaline (p=0.001), and the correct route of administration (p=0.001). Both physicians and nurses preferred adrenaline as the first treatment drug (79.67%, n=192), followed by pheniramine (14.94%, n=36) and glucocorticoids (4.56%, n=11). Furthermore, 69.8% (n=167) of participants correctly answered the question about the adult adrenaline dose. Conclusion: Healthcare personnel, including physicians, lack sufficient knowledge of anaphylaxis diagnosis and treatment. Since anaphylaxis is a condition requiring urgent intervention and can be fatal if left untreated, the knowledge and skills of all personnel should be improved to minimize the risk of delayed treatment and serious complications.
- 5 July 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-6
Interval prolongation is an effective and well-tolerated approach when stepping down omalizumab treatment in chronic spontaneous urticaria
- 5 July 2025
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 317 (1) , 1-6
Interval prolongation is an effective and well-tolerated approach when stepping down omalizumab treatment in chronic spontaneous urticaria
- 15 May 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (9) , 1512-1524
Distinct characteristics of asthma overlap phenotypes: Insights from the Turkish adult asthma registry
Considerable overlaps exist between asthma phenotypes and the clinical significance of these overlaps remains undetermined. The objective of this study is to analyze the characteristics of asthma overlap phenotypes using data from the Turkish Adult Asthma Registry (TAAR). This cross-sectional registry study included 2053 adult patients (74.8% female) with asthma. Overall, 39.3% (n = 697) had allergic-eosinophilic (AE), 26.0% (n = 461) had allergic-non-eosinophilic (ANE), 21.3% (n = 377) had non-allergic-eosinophilic (NAE), and 13.4% (n = 237) had non-allergic-non-eosinophilic (NANE) asthma. Severe asthma exacerbations and emergency department (ED) visits were more frequent in the AE (28.3%, 31.2%, respectively) and NAE groups (36.0%, 34.0%, respectively) than in the ANE (14.3%, 20.6%, respectively) and NANE groups (12.6%, 16.7%, respectively) (p < 0.001). FEV1 values were significantly lower in the AE group than in the ANE and NANE groups (p < 0.001, p = 0.048, respectively) and in the NAE group than in the ANE group (p < 0.001). Risk factors for poor asthma control included living in rural areas, asthma-related ED visits, FEV1 < 60% in the NAE; being overweight, chronic rhinosinusitis, oral corticosteroids use, age < 40 years in the NANE; FEV1 < 80% in the AE; and severe asthma exacerbations, ED visits for AE and ANE groups. The considerable overlap between allergic and eosinophilic asthma phenotypes has clinical implications as increased rates of asthma exacerbations and healthcare utilization. The clinical heterogeneity among asthma phenotypes based on a single biomarker highlights the importance of multidimensional asthma phenotyping.
- 15 May 2025
- Published by Taylor & Francis in Journal of Asthma
- Vol. 62 (9) , 1512-1524
Distinct characteristics of asthma overlap phenotypes: Insights from the Turkish adult asthma registry
Considerable overlaps exist between asthma phenotypes and the clinical significance of these overlaps remains undetermined. The objective of this study is to analyze the characteristics of asthma overlap phenotypes using data from the Turkish Adult Asthma Registry (TAAR). This cross-sectional registry study included 2053 adult patients (74.8% female) with asthma. Overall, 39.3% (n = 697) had allergic-eosinophilic (AE), 26.0% (n = 461) had allergic-non-eosinophilic (ANE), 21.3% (n = 377) had non-allergic-eosinophilic (NAE), and 13.4% (n = 237) had non-allergic-non-eosinophilic (NANE) asthma. Severe asthma exacerbations and emergency department (ED) visits were more frequent in the AE (28.3%, 31.2%, respectively) and NAE groups (36.0%, 34.0%, respectively) than in the ANE (14.3%, 20.6%, respectively) and NANE groups (12.6%, 16.7%, respectively) (p < 0.001). FEV1 values were significantly lower in the AE group than in the ANE and NANE groups (p < 0.001, p = 0.048, respectively) and in the NAE group than in the ANE group (p < 0.001). Risk factors for poor asthma control included living in rural areas, asthma-related ED visits, FEV1 < 60% in the NAE; being overweight, chronic rhinosinusitis, oral corticosteroids use, age < 40 years in the NANE; FEV1 < 80% in the AE; and severe asthma exacerbations, ED visits for AE and ANE groups. The considerable overlap between allergic and eosinophilic asthma phenotypes has clinical implications as increased rates of asthma exacerbations and healthcare utilization. The clinical heterogeneity among asthma phenotypes based on a single biomarker highlights the importance of multidimensional asthma phenotyping.
- Open Access
- 1 May 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 52 (3) , 1-7
Genetic predisposition and increased environmental allergen exposure in cat allergy: The pandemic is a very good example
Objective: Domestic cats are among the most common sources of indoor allergens. There was an increase in indoor allergen exposure, especially cats and house dust mites, as people spent more time at home during the COVID-19 pandemic lockdowns. In this study, our aim was to examine the frequency of cat sensitization and ownership after the COVID-19 pandemic and its relationship with other indoor and pollen allergen sensitizations. Methods: The data of patients who applied to our clinic between 2018 and 2022, with a history of hypersensitivity reaction after contact with cats and diagnosed with cat allergy by positive skin test or specific immunoglobulin E (sIgE) level, were examined retrospectively. Skin test was performed in accordance with the manufacturer’s instructions. sIgE levels against cat allergens were measured using The Phadia CAP System FEIA method. Results: There has been an increase in the rate of cat ownership (P < 0.001) during the COVID-19 pandemic. The prevalence of cat allergy in 2020 and beyond (5.89%) was significantly higher than the pre-COVID period (4.53%; P < 0.001). The prevalence of concomitant df (dermatophagoides farinae) (1.53–1.58%), dp (dermatophagoides pterynossinus) (1.53–1.48%), and pollen (3.47–3.62%) hypersensitivity before COVID-19 did not differ significantly after COVID, but the prevalence of “penicillium” hypersensitivity before COVID (= 8/5825) was found to be significantly lower (0.14–1.28%). Conclusion: During the pandemic period, both the increase in cat ownership and spending more time indoors seem to have led to an increase in cat allergy. No increase in indoor allergen sensitization other than penicillium accompanying cat allergy was detected.
- 1 May 2025
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 52 (3) , 1-7
Open AccessGenetic predisposition and increased environmental allergen exposure in cat allergy: The pandemic is a very good example
Objective: Domestic cats are among the most common sources of indoor allergens. There was an increase in indoor allergen exposure, especially cats and house dust mites, as people spent more time at home during the COVID-19 pandemic lockdowns. In this study, our aim was to examine the frequency of cat sensitization and ownership after the COVID-19 pandemic and its relationship with other indoor and pollen allergen sensitizations. Methods: The data of patients who applied to our clinic between 2018 and 2022, with a history of hypersensitivity reaction after contact with cats and diagnosed with cat allergy by positive skin test or specific immunoglobulin E (sIgE) level, were examined retrospectively. Skin test was performed in accordance with the manufacturer’s instructions. sIgE levels against cat allergens were measured using The Phadia CAP System FEIA method. Results: There has been an increase in the rate of cat ownership (P < 0.001) during the COVID-19 pandemic. The prevalence of cat allergy in 2020 and beyond (5.89%) was significantly higher than the pre-COVID period (4.53%; P < 0.001). The prevalence of concomitant df (dermatophagoides farinae) (1.53–1.58%), dp (dermatophagoides pterynossinus) (1.53–1.48%), and pollen (3.47–3.62%) hypersensitivity before COVID-19 did not differ significantly after COVID, but the prevalence of “penicillium” hypersensitivity before COVID (= 8/5825) was found to be significantly lower (0.14–1.28%). Conclusion: During the pandemic period, both the increase in cat ownership and spending more time indoors seem to have led to an increase in cat allergy. No increase in indoor allergen sensitization other than penicillium accompanying cat allergy was detected.
- Open Access
- 24 April 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (6) , 1008-1022
What Does Radiologic Assessment Contribute to Asthma: A Subanalysis of the Turkish Adult Asthma Registry
Objectives: It is aimed to assess how physicians use chest imaging in asthma and the relationship between the pathological findings and related disease characteristics in the radiological imaging of asthmatic patients. Background: The daily practice of imaging and its contribution to the management of asthma are not well defined. It is common to use radiological imaging to investigate pathologies that cause respiratory symptoms and to evaluate differential diagnoses in asthma patients. In this study, as a subanalysis of the Turkish Adult Asthma Registry, radiological findings and outcomes of asthmatic patients were examined. Methods: Between March 2018 and March 2022, the data of asthma patients in 36 secondary and tertiary health care centers was recorded using a web-based application. Patients with chest X-ray, computed thorax tomography, and paranasal sinus tomography data in the asthma database were statistically evaluated for sub-analysis. Results: The study included 2053 patients. Chest X-rays were taken in the majority of the cases (n:1739; 84.7%). Computed thorax tomography was performed in 869 (42.3%) patients and paranasal sinus tomography in 388 (18.9%) patients. The most common pathological findings on chest X-rays of asthmatic patients were increased bronchovascular branching and dirty lung appearance, whereas they were linear atelectasis, and bronchial wall thickening on computed thorax tomography bronchiectasis. Soft tissue in the sinuses and nasal polyps were the most common pathological findings in paranasal sinus tomography. Pathological findings were much more common in the radiological evaluations of patients with eosinophilic and allergic phenotypes and in patients with severe asthma. Conclusion: The radiological findings of asthma vary depending on the phenotype and severity of the disease. Patients with asthma, particularly those in the high-risk group, should be evaluated from a radiological perspective.
- 24 April 2025
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 126 (6) , 1008-1022
Open AccessWhat Does Radiologic Assessment Contribute to Asthma: A Subanalysis of the Turkish Adult Asthma Registry
Objectives: It is aimed to assess how physicians use chest imaging in asthma and the relationship between the pathological findings and related disease characteristics in the radiological imaging of asthmatic patients. Background: The daily practice of imaging and its contribution to the management of asthma are not well defined. It is common to use radiological imaging to investigate pathologies that cause respiratory symptoms and to evaluate differential diagnoses in asthma patients. In this study, as a subanalysis of the Turkish Adult Asthma Registry, radiological findings and outcomes of asthmatic patients were examined. Methods: Between March 2018 and March 2022, the data of asthma patients in 36 secondary and tertiary health care centers was recorded using a web-based application. Patients with chest X-ray, computed thorax tomography, and paranasal sinus tomography data in the asthma database were statistically evaluated for sub-analysis. Results: The study included 2053 patients. Chest X-rays were taken in the majority of the cases (n:1739; 84.7%). Computed thorax tomography was performed in 869 (42.3%) patients and paranasal sinus tomography in 388 (18.9%) patients. The most common pathological findings on chest X-rays of asthmatic patients were increased bronchovascular branching and dirty lung appearance, whereas they were linear atelectasis, and bronchial wall thickening on computed thorax tomography bronchiectasis. Soft tissue in the sinuses and nasal polyps were the most common pathological findings in paranasal sinus tomography. Pathological findings were much more common in the radiological evaluations of patients with eosinophilic and allergic phenotypes and in patients with severe asthma. Conclusion: The radiological findings of asthma vary depending on the phenotype and severity of the disease. Patients with asthma, particularly those in the high-risk group, should be evaluated from a radiological perspective.
- Open Access
- 23 March 2025
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 73 (1) , 52-59
Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?
The negative effects of eosinophilic severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) on quality of life are well known. The present study aimed to evaluate the impact of mepolizumab treatment on the quality of life of patients diagnosed with eosinophilic severe asthma and CRSwNP. Patients with CRSwNP and eosinophilic severe asthma who had been receiving mepolizumab 100 mg/month for at least six months as treatment were eligible for the study. Patients were assessed using quality of life and disease control questionnaires for both diseases before and during the sixth month of treatment. Forty-nine patients were included in the present study. Compared to the pre-treatment period, there was significant clinical improvement in quality of life for both rhinitis and asthma following mepolizumab treatment. The changes before and after the treatment were found as follows: Rhinitis Quality of Life Scale [44 (23-72); 25 (6-57); p< 0.001], Nasal Congestion Symptom Assessment Scale [13.0 (8-20); 9.0 (0-20); p< 0.001], Sino-Nasal Outcomes Test-22 (63.16 ± 17.9; 44.16 ± 21.33; p< 0.001), Asthma Quality of Life Questionnaire (111.06 ± 25.17; 142.67 ± 28.04; p< 0.001), Asthma Control Test [16 (6-21); 22 (14-25); p< 0.001]. Before mepolizumab treatment, 20 patients defined that CRSwNP and 29 patients defined that asthma affected their quality of life primarily. After six months of mepolizumab treatment, 38 patients defined that CRSwNP and 11 patients defined that asthma affected their quality of life primarily. Our results showed that mepolizumab is an effective treatment option for eosinophilic severe asthma and CRSwNP in patients having both diseases. Before mepolizumab, most patients' quality of life was affected by asthma symptoms, but this changed, and their quality of life began to be affected primarily by CRSwNP symptoms. This suggests that mepolizumab treatment is more effective in suppressing asthma symptoms than suppressing nasal polyp symptoms.
- 23 March 2025
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 73 (1) , 52-59
Open AccessMepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?
The negative effects of eosinophilic severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) on quality of life are well known. The present study aimed to evaluate the impact of mepolizumab treatment on the quality of life of patients diagnosed with eosinophilic severe asthma and CRSwNP. Patients with CRSwNP and eosinophilic severe asthma who had been receiving mepolizumab 100 mg/month for at least six months as treatment were eligible for the study. Patients were assessed using quality of life and disease control questionnaires for both diseases before and during the sixth month of treatment. Forty-nine patients were included in the present study. Compared to the pre-treatment period, there was significant clinical improvement in quality of life for both rhinitis and asthma following mepolizumab treatment. The changes before and after the treatment were found as follows: Rhinitis Quality of Life Scale [44 (23-72); 25 (6-57); p< 0.001], Nasal Congestion Symptom Assessment Scale [13.0 (8-20); 9.0 (0-20); p< 0.001], Sino-Nasal Outcomes Test-22 (63.16 ± 17.9; 44.16 ± 21.33; p< 0.001), Asthma Quality of Life Questionnaire (111.06 ± 25.17; 142.67 ± 28.04; p< 0.001), Asthma Control Test [16 (6-21); 22 (14-25); p< 0.001]. Before mepolizumab treatment, 20 patients defined that CRSwNP and 29 patients defined that asthma affected their quality of life primarily. After six months of mepolizumab treatment, 38 patients defined that CRSwNP and 11 patients defined that asthma affected their quality of life primarily. Our results showed that mepolizumab is an effective treatment option for eosinophilic severe asthma and CRSwNP in patients having both diseases. Before mepolizumab, most patients' quality of life was affected by asthma symptoms, but this changed, and their quality of life began to be affected primarily by CRSwNP symptoms. This suggests that mepolizumab treatment is more effective in suppressing asthma symptoms than suppressing nasal polyp symptoms.
- Open Access
- 25 January 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (1) , e70018
Socioeconomic status has direct impact on asthma control: Turkish adult asthma registry
Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma‐related death.Objective: In this study, we aimed to determine socioeconomic levels of asthmatic patients according to a national database and investigate the effects of social markers on disease control in our region.Methods: This is an analysis of data from 2053 adult asthma patients from a multicentre chart study in Turkey. Socioeconomic status (SES) data were collected from questionnaires and this form was sent to the patients via e‐mail. Parameters related to social status and poor disease control were analyzed.Results: Illiteracy (OR:2.687 [95% CI: 1.235–5.848]; p = 0.013) and lower household income (OR:1,76 [95% CI: 1.002–3.09]; p = 0.049) were found as independent risk factors for hospitalization in the multivariate logistic regression analysis. Therewithal, being aged between 40 and 60 (OR: 1.435 [95% CI: 1.074–1.917]; p = 0.015), illiteracy (OR: 2.188 [95% CI: 1.262–3.795]; p = 0.005) and being employed (OR: 1.466 [95% CI: 1.085–1.847]; p = 0.011) were considered as independent risk factors for systemic corticosteroid use at least 3 days within last 1 year.Conclusion: As a result of our national database, education level, household income and working status briefly socioeconomic status have impacts on asthma control. Identification of social markers in asthma and better recognition of risk factors based on the population gives us clues to provide better asthma control in the future.
- 25 January 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (1) , e70018
Open AccessSocioeconomic status has direct impact on asthma control: Turkish adult asthma registry
Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma‐related death.Objective: In this study, we aimed to determine socioeconomic levels of asthmatic patients according to a national database and investigate the effects of social markers on disease control in our region.Methods: This is an analysis of data from 2053 adult asthma patients from a multicentre chart study in Turkey. Socioeconomic status (SES) data were collected from questionnaires and this form was sent to the patients via e‐mail. Parameters related to social status and poor disease control were analyzed.Results: Illiteracy (OR:2.687 [95% CI: 1.235–5.848]; p = 0.013) and lower household income (OR:1,76 [95% CI: 1.002–3.09]; p = 0.049) were found as independent risk factors for hospitalization in the multivariate logistic regression analysis. Therewithal, being aged between 40 and 60 (OR: 1.435 [95% CI: 1.074–1.917]; p = 0.015), illiteracy (OR: 2.188 [95% CI: 1.262–3.795]; p = 0.005) and being employed (OR: 1.466 [95% CI: 1.085–1.847]; p = 0.011) were considered as independent risk factors for systemic corticosteroid use at least 3 days within last 1 year.Conclusion: As a result of our national database, education level, household income and working status briefly socioeconomic status have impacts on asthma control. Identification of social markers in asthma and better recognition of risk factors based on the population gives us clues to provide better asthma control in the future.
- 29 November 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 236, 107883
Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry
- 29 November 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 236, 107883
Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry
- 1 August 2023
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 36 (4) , 189-209
The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma
The journey of using anticholinergics in the treatment of asthma started with anticholinergic-containing plants such as Datura stramonium and Atropa belladonna, followed by ipratropium bromide and continued with tiotropium, glycopyrronium, and umeclidinium. Although antimuscarinics were used in the maintenance treatment of asthma over a century ago, after a long time (since 2014), it has been recommended to be used as an add-on long-acting antimuscarinic agent (LAMA) therapy in the maintenance treatment of asthma. The airway tone controlled by the vagus nerve is increased in asthma. Allergens, toxins, or viruses cause airway inflammation and inflammation-related epithelial damage, increased sensory nerve stimulation, ganglionic and postganglionic acetylcholine (ACh) release by inflammatory mediators, intensification of ACh signaling at M1 and M3 muscarinic ACh receptors (mAChRs), and dysfunction of M2 mAChR. Optimal anticholinergic drug for asthma should effectively block M3 and M1 receptors, but have minimal effect on M2 receptors. Tiotropium, umeclidinium, and glycopyrronium are anticholinergic agents with this feature. Tiotropium has been used in a separate inhaler as an add-on treatment to inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA), and glycopyrronium and umeclidinium have been used in a single inhaler as a combination of ICS/LABA/LAMA in asthma in recent years. Guidelines recommend this regimen as an optimization step for patients with severe asthma before initiating any biologic or systemic corticosteroid therapy. In this review, the history of antimuscarinic agents, their effectiveness and safety in line with randomized controlled trials, and real-life studies in asthma treatment will be discussed according to the current data.
- 1 August 2023
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 36 (4) , 189-209
The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma
The journey of using anticholinergics in the treatment of asthma started with anticholinergic-containing plants such as Datura stramonium and Atropa belladonna, followed by ipratropium bromide and continued with tiotropium, glycopyrronium, and umeclidinium. Although antimuscarinics were used in the maintenance treatment of asthma over a century ago, after a long time (since 2014), it has been recommended to be used as an add-on long-acting antimuscarinic agent (LAMA) therapy in the maintenance treatment of asthma. The airway tone controlled by the vagus nerve is increased in asthma. Allergens, toxins, or viruses cause airway inflammation and inflammation-related epithelial damage, increased sensory nerve stimulation, ganglionic and postganglionic acetylcholine (ACh) release by inflammatory mediators, intensification of ACh signaling at M1 and M3 muscarinic ACh receptors (mAChRs), and dysfunction of M2 mAChR. Optimal anticholinergic drug for asthma should effectively block M3 and M1 receptors, but have minimal effect on M2 receptors. Tiotropium, umeclidinium, and glycopyrronium are anticholinergic agents with this feature. Tiotropium has been used in a separate inhaler as an add-on treatment to inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA), and glycopyrronium and umeclidinium have been used in a single inhaler as a combination of ICS/LABA/LAMA in asthma in recent years. Guidelines recommend this regimen as an optimization step for patients with severe asthma before initiating any biologic or systemic corticosteroid therapy. In this review, the history of antimuscarinic agents, their effectiveness and safety in line with randomized controlled trials, and real-life studies in asthma treatment will be discussed according to the current data.
- 31 May 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (11) , 1973-1986
Picturing asthma in Turkey: results from the Turkish adult asthma registry
National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry ...
- 31 May 2023
- Published by Taylor & Francis in Journal of Asthma
- Vol. 60 (11) , 1973-1986
Picturing asthma in Turkey: results from the Turkish adult asthma registry
National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry ...